Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions Inc. (NYSE: EBS) regularly issues news and updates that reflect its focus on public health threats and pharmaceutical preparation manufacturing. Company announcements highlight developments across its commercial naloxone franchise, medical countermeasures portfolio, manufacturing network and financial performance, providing context for how Emergent pursues its stated mission to protect and save lives.
News items frequently cover product and regulatory milestones, such as U.S. Food and Drug Administration approvals and supplemental applications. Examples include FDA approval of over‑the‑counter NARCAN® Naloxone HCl Nasal Spray 4 mg and approval of a supplemental Biologics License Application for raxibacumab manufacturing at Emergent’s Winnipeg, Canada facility. Releases also describe new packaging options, such as the NARCAN® Nasal Spray carrying case designed to make naloxone easier to carry and more discreet.
Emergent’s news flow also features government contracts and contract modifications for medical countermeasures. Recent announcements describe delivery orders and options to supply BioThrax® (Anthrax Vaccine Adsorbed), ACAM2000® (Smallpox (Vaccinia) Vaccine, Live), CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), TEMBEXA® and BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to U.S. government agencies responsible for preparedness and response.
Investors and observers can also find financial and corporate updates, including quarterly earnings releases, segment performance commentary, debt prepayments under term loan facilities, and notices of presentations at healthcare conferences. Additional news addresses board‑level changes and corporate governance matters.
Other communications focus on public health initiatives and collaborations, such as support for opioid poisoning awareness observances, partnerships aimed at increasing workplace access to naloxone, and collaboration with PANTHER and Africa CDC on the MpOx Study in Africa. Together, these updates offer insight into how Emergent’s products, contracts, research collaborations and financial decisions relate to its role in addressing health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies.
Emergent BioSolutions (NYSE: EBS) will hold a conference call on July 30, 2020, at 5:00 pm ET to discuss Q2 2020 financial results and provide revenue guidance for Q3 and the full year. The call can be accessed via telephone or webcast. Investors can view the live feed through the company’s website.
Emergent is focused on enhancing public health through innovative life sciences solutions, with a mission to protect 1 billion lives by 2030.
Emergent BioSolutions (NYSE: EBS) announced a $75 million investment to expand its Canton, Massachusetts facility, focusing on advanced therapy contract development and manufacturing (CDMO) services. This expansion aims to enhance capabilities in viral vector and gene therapy, with services expected to launch in 2023. The improved facility will enable molecule-to-market CDMO services integrating development, drug substance, and drug product manufacturing across its locations in Gaithersburg and Rockville, Maryland. This strategic move aligns with Emergent's growth plan and enhances its position in public health solutions.
Emergent BioSolutions (NYSE: EBS) announced participation in two key virtual investor conferences in June 2020. The events include the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on June 23, featuring a fireside chat at 3:00 PM Eastern, and the Three Part Advisors Virtual East Coast IDEAS Investor Conference on June 24, offering a pre-recorded presentation available from 8:00 AM Eastern. The webcasts will cover recent business developments and financial guidance, accessible via the Emergent website.
Emergent BioSolutions (EBS) has signed an $87 million agreement to provide contract development and manufacturing services for AstraZeneca's COVID-19 vaccine, AZD1222. This partnership supports Operation Warp Speed, aiming to deliver a vaccine by January 2021. Emergent will utilize its Gaithersburg facility for development and its Baltimore Bayview facility for large-scale manufacturing, capable of producing tens to hundreds of millions of vaccine doses annually. The company plans to update its 2020 financial outlook in Q2 financial results.
The U.S. District Court for the District of New Jersey ruled in favor of Teva Pharmaceuticals in the patent litigation concerning NARCAN® Nasal Spray 4mg/spray. Emergent BioSolutions plans to appeal the decision to the Court of Appeals for the Federal Circuit. Doug White, a senior executive at Emergent, expressed disappointment but reaffirmed the company’s commitment to improve access to NARCAN® and aid in combating the opioid crisis. Emergent will update its 2020 financial outlook related to this case and its COVID-19 initiatives during the second quarter financial results announcement.
Emergent BioSolutions has expanded its partnership with HHS through a $628 million task order under its 2012 contract with BARDA. This task order supports rapid COVID-19 vaccine production, committing $542.7 million to CDMO services and $85.5 million for fill/finish capacity expansion. Emergent aims to strengthen the U.S.-based manufacturing supply chain for pharmaceutical innovators, leveraging its Baltimore Bayview facility's significant production capabilities. The company's long-standing relationship with the government highlights its key role in addressing public health needs.
Emergent BioSolutions announced its 2020 Annual Meeting of Stockholders will be held virtually on May 21, 2020, at 9:00 AM EDT due to the COVID-19 pandemic. Stockholders of record as of March 26, 2020, can participate by visiting the company’s virtual meeting site. Only those with a Control Number can ask questions; others can attend in listen-only mode. Detailed instructions for participation are provided, with a replay of the meeting available on the company’s website afterward. The company aims to protect public health and enhance life through its products and services.
Summary not available.